Diabetic retinopathy treatment with stabilized dexamethasone
A method is described of stabilizing the pH of an aqueous composition including a drug that is prone to oxidation. The method includes adding an additive to prevent oxidation of the drug that is prone to oxidation. Also described, is a method of stabilizing the pH of an aqueous composition including a corticosteroid, the method including adding an additive to prevent oxidation of the corticosteroid. Further, a composition is described that includes a corticosteroid and an additive to prevent oxidation of the corticosteroid.
1. A method of treating diabetic retinopathy in a human subject in need thereof, comprising topically administering to an affected eye of the subject an aqueous ophthalmic composition from a plastic container that allows oxidation of its contents, the composition comprising:
i) between 1% and 4% weight to volume (w/v) of dexamethasone;
ii) between 5% and 25% w/v of γ-cyclodextrin;
iii) between 2.2% and 2.8% w/v of a poloxamer;
iv) between 0% and 0.2% w/v of disodium edetate;
v) between 0% and 1% w/v of an electrolyte;
vi) between 0.1% and 0.5% w/v of sodium thiosulfate; and,
vii) water;
wherein the composition comprises a microsuspension comprising solid complexes of dexamethasone and γ-cyclodextrin.
2. The method of claim 1 , wherein the aqueous ophthalmic composition comprises 1.5% w/v of dexamethasone.
3. The method of claim 1 , wherein the aqueous ophthalmic composition comprises 14% w/v of γ-cyclodextrin.
4. The method of claim 1 , wherein the aqueous ophthalmic composition comprises 2.5% w/v of the poloxamer.
5. The method of claim 4 , wherein the poloxamer is selected from the group consisting of poloxamer 101, poloxamer 105, poloxamer 108, poloxamer 122, poloxamer 123, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 183, poloxamer 184, poloxamer 185, poloxamer 188, poloxamer 212, poloxamer 215, poloxamer 217, poloxamer 231, poloxamer 234, poloxamer 235, poloxamer 237, poloxamer 238, poloxamer 282, poloxamer 284, poloxamer 288, poloxamer 331, poloxamer 333, poloxamer 334, poloxamer 335, poloxamer 338, poloxamer 401, poloxamer 402, poloxamer 403, poloxamer 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate.
6. The method of claim 5 , wherein the poloxamer is poloxamer 407.
7. The method of claim 1 , wherein the aqueous ophthalmic composition comprises 0.1% w/v of disodium edetate.
8. The method of claim 1 , wherein the electrolyte is selected from the group consisting of sodium chloride and potassium chloride.
9. The method of claim 8 , wherein the electrolyte is sodium chloride.
10. The method of claim 9 , wherein the aqueous ophthalmic composition comprises 0.57% w/v of sodium chloride.
11. The method of claim 1 , wherein the aqueous ophthalmic composition comprises 0.3% w/v of sodium thiosulfate which corresponds to water-free sodium thiosulfate.
12. The method of claim 11 , wherein the sodium thiosulfate is sodium thiosulfate pentahydrate.
13. The method of claim 1 , wherein the solid complexes comprise microparticles comprising a diameter D 50 ranging from about 1 μm to 10 μm.
14. The method of claim 1 , wherein the aqueous ophthalmic composition has a pH of between 4.5 and 6.
15. The method of claim 1 , wherein the subject is vascular epithelial growth factor (VEGF) inhibitor naïve.
16. The method of claim 1 , wherein the subject has diabetic macular edema (DME).
17. The method of claim 16 , wherein the subject has retinal thickening due to DME.
18. The method of claim 1 , wherein the container is made of low-density polyethylene (LDPE).
19. A method of treating diabetic retinopathy in a human subject in need thereof, comprising topically administering to an affected eye of the subject an aqueous ophthalmic composition from a plastic container that allows oxidation of its contents, the composition comprising:
i) 1.5% w/v of dexamethasone;
ii) 14% w/v of γ-cyclodextrin;
iii) 2.5% w/v of poloxamer 407;
iv) 0.1% w/v of disodium edetate;
v) 0.57% w/v of sodium chloride;
vi) between 0.2% and 0.4% w/v of sodium thiosulfate; and,
vii) water;
wherein the composition comprises a microsuspension comprising solid complexes of dexamethasone and γ-cyclodextrin.
20. The method of claim 19 , wherein the solid complexes comprise microparticles comprising a diameter D 50 ranging from about 1 μm to 10 μm.
21. The method of claim 19 , wherein the aqueous ophthalmic composition comprises 0.3% w/v of sodium thiosulfate which corresponds to water-free sodium thiosulfate.
22. The method of claim 21 , wherein the sodium thiosulfate is sodium thiosulfate pentahydrate.
23. The method of claim 19 , wherein the aqueous ophthalmic composition has a pH of between 4.5 and 6.
24. The method of claim 19 , wherein the container is made of low-density polyethylene.
25. The method of claim 19 , wherein the subject is vascular epithelial growth factor (VEGF) inhibitor naïve.
26. The method of claim 19 , wherein the subject has diabetic macular edema (DME).
27. The method of claim 26 , wherein the subject has retinal thickening due to DME.